Aurinia Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AUPH and other ETFs, options, and stocks.About AUPH
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.
CEOPeter S. Greenleaf
CEOPeter S. Greenleaf
Employees130
Employees130
HeadquartersEdmonton, Alberta
HeadquartersEdmonton, Alberta
Founded1993
Founded1993
Employees130
Employees130
AUPH Key Statistics
Market cap2.04B
Market cap2.04B
Price-Earnings ratio27.36
Price-Earnings ratio27.36
Dividend yield—
Dividend yield—
Average volume2.48M
Average volume2.48M
High today$15.78
High today$15.78
Low today$15.15
Low today$15.15
Open price$15.25
Open price$15.25
Volume1.39M
Volume1.39M
52 Week high$16.20
52 Week high$16.20
52 Week low$6.55
52 Week low$6.55
Stock Snapshot
The current Aurinia Pharmaceuticals(AUPH) stock price is $15.39, with a market capitalization of 2.04B. The stock trades at a price-to-earnings (P/E) ratio of 27.36.
On 2025-11-18, Aurinia Pharmaceuticals(AUPH) stock moved within a range of $15.15 to $15.78. With shares now at $15.39, the stock is trading +1.6% above its intraday low and -2.5% below the session's peak.
Trading volume for Aurinia Pharmaceuticals(AUPH) stock has reached 1.39M, versus its average volume of 2.48M.
The stock's 52-week range extends from a low of $6.55 to a high of $16.20.
The stock's 52-week range extends from a low of $6.55 to a high of $16.20.
Analyst ratings
71%
of 7 ratingsBuy
71.4%
Hold
28.6%
Sell
0%
People also own
Based on the portfolios of people who own AUPH. This list is generated using Robinhood data, and it’s not a recommendation.